All Stories

  1. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study
  2. Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series
  3. The use of medical grade cannabis in Italy for drug-resistant epilepsy: a case series
  4. The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families
  5. Overt hypogonadism may be not a sentinel sign of RNF216 : two novel mutations associated with ataxia, chorea and fertility
  6. Olfactory function and cognition in relapsing–remitting and secondary-progressive multiple sclerosis
  7. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis
  8. Cognitive and functional connectivity alterations in Friedreich's ataxia
  9. Dissociative identity disorder: Restoration of executive functions after switch from alter to host personality
  10. Peripheral markers of autophagy in polyglutamine diseases
  11. The Multiple Faces of Spinocerebellar Ataxia type 2
  12. Normalization of timed neuropsychological tests with the PATA rate and nine-hole pegboard tests
  13. The iEDSS: BICAMS for the Cerebral Functional Score
  14. Lamivudine and fingolimod co-administration in two patients with multiple sclerosis and occult hepatitis B virus infection
  15. The use of medical-grade cannabis in patients non-responders to Nabiximols
  16. Mobitz type I and II atrioventricular blocks during fingolimod therapy
  17. Long-term effect of epoetin alfa on clinical and biochemical markers in friedreich ataxia
  18. Modifications of resting state networks in spinocerebellar ataxia type 2
  19. Multiple hormone deficiencies in chronic heart failure
  20. The combined use of conventional MRI and MR spectroscopic imaging increases the diagnostic accuracy in amyotrophic lateral sclerosis
  21. A randomized controlled pilot trial of lithium in spinocerebellar ataxia type 2
  22. Screening for dopa-responsive dystonia in patients with scans without evidence of dopaminergic deficiency (SWEDD)
  23. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial
  24. Safety and tolerability of carbamylated erythropoietin in Friedreich's ataxia
  25. Genetic Screening for the LRRK2 R1441C and G2019S Mutations in Parkinsonian Patients from Campania
  26. A genome-wide association meta-analysis identifies a novel locus at 17q11.2 associated with sporadic amyotrophic lateral sclerosis
  27. A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington Disease
  28. Migraine attack restores the response of vascular smooth muscle cells to nitric oxide but not to norepinephrine
  29. Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene
  30. A randomized clinical trial of lithium in multiple system atrophy
  31. A gene expression phenotype in lymphocytes from friedreich ataxia patients
  32. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results
  33. A Combined Nucleic Acid and Protein Analysis in Friedreich Ataxia: Implications for Diagnosis, Pathogenesis and Clinical Trial Design
  34. Epoetin alfa increases frataxin production in Friedreich's ataxia without affecting hematocrit
  35. Benign hereditary chorea: Clinical and neuroimaging features in an Italian family
  36. Vascular smooth muscle cell dysfunction in patients with migraine
  37. SCA Functional Index: A useful compound performance measure for spinocerebellar ataxia
  38. Recombinant Human Erythropoietin Increases Frataxin Protein Expression Without Increasing mRNA Expression
  39. Ataxia with oculomotor apraxia type 2: A clinical, pathologic, and genetic study
  40. Novel mutation ofSACSgene in a Spanish family with autosomal recessive spastic ataxia
  41. Autosomal recessive progressive myoclonus epilepsy with ataxia and mental retardation
  42. Very late onset in ataxia oculomotor apraxia type I